Healio (8/11, Herpen) reports, “In older adult patients with Alzheimer’s-related dementia, treatment with brexpiprazole resulted in greater reduction in agitation compared with placebo, while proving to be safe and well-tolerated,” investigators concluded in a “12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm study that included 345 patients aged 55 to 90 years, in care facilities or community-based setting.” The findings were presented at the 2022 Alzheimer’s Association International Conference. (SOURCE: APA Headlines)